表紙
市場調査レポート

猫アレルギー:パイプライン分析

Cat Allergy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 246030
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
猫アレルギー:パイプライン分析 Cat Allergy - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 32 Pages
概要

猫アレルギーは、猫が作り出すアレルゲンに対して起こるアレルギー反応です。症状にはくしゃみや鼻水、鼻づまり、鼻づまりが原因の顔面痛、咳、胸部圧迫感、息切れ、喘鳴、涙目、目の充血やかゆみ、発疹、じんましんなどがあります。

当レポートでは、猫アレルギーの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

猫アレルギー 概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • ALK-Abello A/S
  • Amgen Inc.
  • Biomay AG
  • Circassia Pharmaceuticals plc

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Allergen for Cat Allergy
  • Allergen for Cat Allergy
  • BM-36
  • Epsi-Gam
  • tezepelumab
  • Vaccine for Cat Allergy
  • Vaccine for Cat Allergy

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8385IDB

Summary

Global Markets Direct's, 'Cat Allergy - Pipeline Review, H2 2016', provides an overview of the Cat Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cat Allergy
  • The report reviews pipeline therapeutics for Cat Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cat Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Cat Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cat Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cat Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Cat Allergy Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Cat Allergy - Overview 7
  • Cat Allergy - Therapeutics under Development by Companies 8
  • Cat Allergy - Pipeline Products Glance 9
  • Clinical Stage Products 9
  • Early Stage Products 10
  • Cat Allergy - Products under Development by Companies 11
  • Cat Allergy - Companies Involved in Therapeutics Development 12
  • ALK-Abello A/S 12
  • Amgen Inc. 13
  • Biomay AG 14
  • Cat Allergy - Therapeutics Assessment 15
  • Assessment by Monotherapy Products 15
  • Assessment by Target 16
  • Assessment by Mechanism of Action 17
  • Assessment by Route of Administration 18
  • Assessment by Molecule Type 20
  • Drug Profiles 22
  • Allergen for Cat Allergy - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • Allergen for Cat Allergy - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • BM-36 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • tezepelumab - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Vaccine for Cat Allergy - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Cat Allergy - Dormant Projects 28
  • Cat Allergy - Discontinued Products 29
  • Appendix 30
  • Methodology 30
  • Coverage 30
  • Secondary Research 30
  • Primary Research 30
  • Expert Panel Validation 30
  • Contact Us 30
  • Disclaimer 31

List of Tables

  • Number of Products under Development for Cat Allergy, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Clinical Stage Development, H2 2016 9
  • Comparative Analysis by Early Stage Development, H2 2016 10
  • Products under Development by Companies, H2 2016 11
  • Cat Allergy - Pipeline by ALK-Abello A/S, H2 2016 12
  • Cat Allergy - Pipeline by Amgen Inc., H2 2016 13
  • Cat Allergy - Pipeline by Biomay AG, H2 2016 14
  • Assessment by Monotherapy Products, H2 2016 15
  • Number of Products by Stage and Target, H2 2016 16
  • Number of Products by Stage and Mechanism of Action, H2 2016 17
  • Number of Products by Stage and Route of Administration, H2 2016 19
  • Number of Products by Stage and Molecule Type, H2 2016 21
  • Cat Allergy - Dormant Projects, H2 2016 28
  • Cat Allergy - Discontinued Products, H2 2016 29

List of Figures

  • Number of Products under Development for Cat Allergy, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Early Stage Products, H2 2016 10
  • Assessment by Monotherapy Products, H2 2016 15
  • Number of Products by Routes of Administration, H2 2016 18
  • Number of Products by Stage and Routes of Administration, H2 2016 18
  • Number of Products by Molecule Types, H2 2016 20
  • Number of Products by Stage and Molecule Types, H2 2016 20
Back to Top